What's Happening?
Cofactor Genomics, a diagnostics company specializing in precision oncology, has received strategic investments from Labcorp and Ascension Ventures to expand its OncoPrism immunotherapy diagnostic across U.S. cancer care networks. OncoPrism uses machine-learning analysis of tumor RNA to predict immune checkpoint inhibitor response, offering a predictive classification for treatment outcomes. The investment will support the nationwide expansion of OncoPrism, increasing patient access to this diagnostic tool. Labcorp's national diagnostics network and Ascension Ventures' connections with major U.S. health systems will facilitate this expansion.
Why It's Important?
The expansion of OncoPrism could significantly enhance the precision of cancer treatment by providing
clinicians with actionable insights into immunotherapy responses. This diagnostic tool moves beyond traditional prognostic biomarkers, offering predictive insights that can guide treatment decisions. By improving the accuracy of immunotherapy predictions, OncoPrism has the potential to optimize treatment plans, reduce unnecessary treatments, and improve patient outcomes. The collaboration with Labcorp and Ascension Ventures will help integrate this technology into both academic and community oncology settings, broadening its impact across the U.S.
What's Next?
Cofactor Genomics plans to use the investment to further develop its predictive immunotherapy diagnostic portfolio and expand its clinical evidence base. The company will also work on integrating OncoPrism into existing health-system infrastructures, enhancing provider access to this technology. As the demand for precision oncology tools grows, Cofactor Genomics aims to scale its commercial and lab operations to meet this need. The success of this expansion could pave the way for similar advancements in other areas of cancer diagnostics and treatment.
